Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

Recruiting now · Not applicable

Conditions studied: NMIBC

In brief

Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.

Key facts

Study ID
NCT06889623
Run by
Changhai Hospital
People needed
72
Starts
2024-06-01
Expected to finish
2028-06-01
Last updated by the study team
2025-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.